Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE2A | O00408 | 1/20 | 0.49 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | SLC7A5 | Q01650 | 2/20 | 0.42 |
| ▸ | NOS3 | P29474 | 2/20 | 0.42 |
| ▸ | NOS1 | P29475 | 2/20 | 0.42 |
| ▸ | NOS2 | P35228 | 2/20 | 0.42 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.42 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | KDM1A | O60341 | 1/20 | 0.41 |
| ▸ | RCOR1 | Q9UKL0 | 1/20 | 0.41 |
| ▸ | SCN10A | Q9Y5Y9 | 2/20 | 0.40 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1729820 | 0.98 | PDE2A (0.50) | PDE2ASLC6A4TSHRSLC7A5NOS3 | |
| SCHEMBL9209206 | 0.98 | PDE2A (0.50) | PDE2ASLC6A4TSHRSLC7A5NOS3 | |
| SCHEMBL1727845 | 0.98 | PDE2A (0.50) | PDE2ASLC6A4TSHRSLC7A5NOS3 | |
| Hydrochloric Acid SCHEMBL17767241 | 0.96 | PDE2A (0.49) | PDE2ASLC6A4TSHRSLC7A5NOS3 | |
| Hydrochloric Acid SCHEMBL16563438 | 0.96 | PDE2A (0.49) | PDE2ASLC6A4TSHRSLC7A5NOS3 | |
| SCHEMBL13216636 | 0.84 | PDE2A (0.47) | PDE2ASLC6A4TSHRSLC7A5NOS3 | |
| SCHEMBL16563613 | 0.84 | PDE2A (0.47) | PDE2ASLC6A4TSHRSLC7A5NOS3 | |
| Hydrochloric Acid SCHEMBL16563775 | 0.83 | SLC2A1 (0.49) | PDE2ASLC6A4TSHRSLC7A5NOS3 | |
| SCHEMBL28447540 | 0.81 | SLC7A5 (0.44) | PDE2ASLC6A4TSHRSLC7A5SLC6A2 | |
| SCHEMBL1728974 | 0.81 | SLC2A1 (0.55) | PDE2ASLC6A4TSHRSLC7A5NOS3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7256207-B2 | Inhibitors of cathepsin S | IRM LLC (BM) | 2007-08-14 | — | — | US | disclosed |
| US-7173051-B2 | Inhibitors of cathepsin S | IRM, LLC (BM) | 2007-02-06 | — | — | US | disclosed |
| US-20050107368-A1 | Selective in presence of at least one other cathepsin isozyme; such as 1-(5,6-dichloro-benzimidazol-1-ylmethyl)-3,3-dimethyl-butyl [2-(5-fluoro-2,3-dihydro-indol-1-yl)-1-hydroxymethyl-ethyl]carbamate | IRM LLC (BM) | 2005-05-19 | — | — | US | disclosed |
| US-20050049244-A1 | Inhibitors of cathepsin S | IRM LLC (BM) | 2005-03-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050107368-A1 | Selective in presence of at least one other cathepsin isozyme; such as 1-(5,6-dichloro-benzimidazol-1-ylmethyl)-3,3-dimethyl-butyl [2-(5-fluoro-2,3-dihydro-indol-1-yl)-1-hydroxymethyl-ethyl]carbamate | CTSS, CTSZ, CTSV | PDE2A 2990/4885SLC6A4 2644/4885TSHR 3773/4885 |
| US-20050049244-A1 | Inhibitors of cathepsin S | CTSS, CTSB, CTSZ | PDE2A 3760/4885SLC6A4 3366/4885TSHR 3750/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.